Cellular protein factories may contribute to ageing and related diseases

Research finds that the cellular assembly line that produces proteins can stall with age, triggering a snowball effect that increases the output of misfolded proteins. In humans, clumps of misfolded proteins contribute to age-linked...

T cells: their increasing significance in infectious disease diagnosis and research

Peter Wrighton-Smith, CEO of Oxford Immunotec, talks to Bioscience Today about growing understanding of the importance of T cells in protecting us from disease, as well as their critical role in measuring immune responses...

Potential breakthrough in treatment of rare disease

Biotech company Actigen has initiated a clinical development programme for GNR-055, a potentially breakthrough treatment for the life-limiting, rare disease mucopolysaccharidosis II (MPS II) (also known as Hunter syndrome). Occurring in around 1 in...

New treatment on horizon against ‘parasite’ mitochondria

A groundbreaking study has solved the old enigma in mitochondrial DNA disorders and advances the prospect of enhanced treatments for patients. It not only resolves a long-standing conundrum in the molecular pathology of mitochondrial disease,...

Breakthrough access to epigenome and streamlines workflows

In an industry first, biotech pioneers PacBio announce significant enhancements to the Sequel II/IIe platform include methylation calling in native DNA, greatly accelerated sample preparation, and support for gene therapy applications. Californian-based Pacific Biosciences (PacBio)...

Why is Diligent Due Diligence Important?

Alex Bone, Patent Attorney, Partner,  AA Thornton. Background Biopharma merger and acquisition activity was lower in 2021 than in recent years, but the top 10 deals still reached a combined value of over $50 billion. The main...

Cancer cell ‘switch-off’ could aid deadly brain tumour treatment

Researchers believe they may have found a way to strengthen possible treatments for glioblastoma and reduce the speed at which the aggressive tumour progresses. Glioblastoma is the most common primary brain tumour in adults, and,...

A Tale of Two Crises

Unfortunately, it appears that being slow to recognise a crisis is part of the human condition, and medical research has had its fair share. Often there needs to be a key event (or series...

Closing the Loop on personalised healthcare

Precision medicine using personalised treatments has entered mainstream healthcare. Closed Loop Medicine Ltd aims to level the playing field further with its drug and digital combination products. The Cambridge-based healthcare company is developing drug and...

The future of healthcare: enabling a culture of prevention though tech

Our existing healthcare systems are in need of an overdue shift in focus, says Simon Pavitt, Chief Operating Officer, London Technology Club. While the compassion, energy and dedication of healthcare workers should never be...

DMT-assisted therapy: changing the way we think about depressive disorders

A ‘spirit molecule’ from the Amazon could be a game changer in the treatment of major depressive disorders. Dr Carol Routledge, of Small Pharma, talks to Karen Southern about her pioneering work with DMT. Psychedelic...

2022: The year for UK Life Sciences?

Charles Walford, Senior Development Director and Head of Life Sciences, Stanhope PLC, considers the opportunities and challenges facing the UK’s life sciences ecosystem. The past two years have propelled life sciences into the mainstream. The...

Personalised medicine: driving a need for greater diversity

Kate Shaw, CEO of Innovative Trials, investigates one of the biggest challenges facing clinical research today. Personalised medicines, particularly gene and cell therapies, offer new opportunities for treating serious conditions such as muscular dystrophy, cystic fibrosis...

Acesis breaks new ground with novel therapy solution to low testosterone

For the first time in over 70 years, a new testosterone replacement therapy has been unveiled. Dr Vassilios Papadopoulos and Dr Costas Karatzas, co-founders of Acesis BioMed, explain how their ‘first-in-class’ peptide therapeutics could...

Is your Invention Plausible?

Alex Bone, Patent Attorney, Partner,  AA Thornton The market exclusivity provided by a patent can be crucial for allowing a company to obtain a return on their R&D investment. A patent is essentially a deal in which,...

AI used to improve cardiovascular risk prediction

AI startup Owkin and Amgen have announced the results of a three-year project using artificial intelligence to more accurately predict cardiovascular risk. This study demonstrates the ability of AI to improve the way that...